A Multiple-Dose Study of LY3493269 in Healthy Participants
An Open-Label, Multiple-Dose Study to Investigate the Pharmacokinetics of LY3493269 Oral Formulations Administered in a Fed or Fasted State in Healthy Participants
Sponsor: Eli Lilly and Company
Terminated
Following preplanned review of the safety and pharmacokinetic data from Part A, it was determined that sufficient data had been obtained. The decision was made to not proceed with Part B and the study was terminated early.
Other terminated trials from Eli Lilly and Company
A PHASE1 clinical study on Healthy, this trial is terminated or withdrawn. The trial is conducted by Eli Lilly and Company and has accumulated 5 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Feb 2025 — Present [monthly]
Terminated PHASE1
Status: Completed → Terminated
-
Sep 2024 — Feb 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
May 2023 — Sep 2023 [monthly]
Recruiting PHASE1
First recorded
Mar 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .